Sulforaphene suppresses RANKL-induced osteoclastogenesis and LPS-induced bone erosion by activating Nrf2 signaling pathway.

[1]  Jiake Xu,et al.  Pharmacology-based molecular docking of 4-methylcatechol and its role in RANKL-mediated ROS/Keap1/Nrf2 signalling axis and osteoclastogenesis. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Xulei Tang,et al.  The Role of NRF2 in Bone Metabolism – Friend or Foe? , 2022, Frontiers in Endocrinology.

[3]  Jinmin Zhao,et al.  Oroxylin A reduces osteoclast formation and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation. , 2021, Biochemical pharmacology.

[4]  Jiake Xu,et al.  Notopterol Attenuates Estrogen Deficiency-Induced Osteoporosis via Repressing RANKL Signaling and Reactive Oxygen Species , 2021, Frontiers in Pharmacology.

[5]  Jeff S. Kimball,et al.  Oxidative Stress and Osteoporosis. , 2021, The Journal of bone and joint surgery. American volume.

[6]  Eun-Young Kim,et al.  Lumican Inhibits Osteoclastogenesis and Bone Resorption by Suppressing Akt Activity , 2021, International journal of molecular sciences.

[7]  Xiaobo Zhu,et al.  Nrf2 epigenetic derepression induced by running exercise protects against osteoporosis , 2021, Bone Research.

[8]  Xiazhou Fu,et al.  Sulforaphane Inhibits Osteoclastogenesis via Suppression of the Autophagic Pathway , 2021, Molecules.

[9]  Qipeng Yuan,et al.  Identifying the p65-Dependent Effect of Sulforaphene on Esophageal Squamous Cell Carcinoma Progression via Bioinformatics Analysis , 2020, International journal of molecular sciences.

[10]  Yue Liu,et al.  Sulforaphene Ameliorates Neuroinflammation and Hyperphosphorylated Tau Protein via Regulating the PI3K/Akt/GSK-3β Pathway in Experimental Models of Alzheimer's Disease , 2020, Oxidative medicine and cellular longevity.

[11]  Xuanyuan Lu,et al.  Vitexin suppresses RANKL‐induced osteoclastogenesis and prevents lipopolysaccharide (LPS)‐induced osteolysis , 2019, Journal of cellular physiology.

[12]  Boya Zhang,et al.  The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling , 2019, Redox biology.

[13]  O. Lamy,et al.  Stopping Denosumab , 2019, Current Osteoporosis Reports.

[14]  HongJin Lee,et al.  Sulforaphene Inhibition of Adipogenesis via Hedgehog Signaling in 3T3-L1 Adipocytes. , 2018, Journal of agricultural and food chemistry.

[15]  Masayuki Yamamoto,et al.  The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. , 2018, Physiological reviews.

[16]  Tingting Li,et al.  Traditional herbal medicine-derived sulforaphene promotes mitophagic cell death in lymphoma cells through CRM1-mediated p62/SQSTM1 accumulation and AMPK activation. , 2018, Chemico-biological interactions.

[17]  Jacques P. Brown,et al.  10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. , 2017, The lancet. Diabetes & endocrinology.

[18]  Dean P. Jones,et al.  Redox theory of aging: implications for health and disease , 2017, Clinical science.

[19]  K. Itoh,et al.  Effects of deficiency of Kelch‐like ECH‐associated protein 1 on skeletal organization: a mechanism for diminished nuclear factor of activated T cells cytoplasmic 1 during osteoclastogenesis , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  Mi-Bo Kim,et al.  Relationship between Chemical Structure and Antimicrobial Activities of Isothiocyanates from Cruciferous Vegetables against Oral Pathogens. , 2016, Journal of microbiology and biotechnology.

[21]  Qipeng Yuan,et al.  The natural compound sulforaphene, as a novel anticancer reagent, targeting PI3K-AKT signaling pathway in lung cancer , 2016, Oncotarget.

[22]  Qipeng Yuan,et al.  Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1 , 2016, Breast Cancer Research and Treatment.

[23]  Jieun Song,et al.  Sulforaphene Interferes with Human Breast Cancer Cell Migration and Invasion through Inhibition of Hedgehog Signaling. , 2016, Journal of agricultural and food chemistry.

[24]  R. Horta,et al.  Resection and microvascular reconstruction of bisphosphonate‐related osteonecrosis of the jaw: The role of microvascular reconstruction , 2016, Head & neck.

[25]  Shan Liu,et al.  Anti-osteoclastogenic activity of isoliquiritigenin via inhibition of NF-κB-dependent autophagic pathway. , 2016, Biochemical pharmacology.

[26]  Jiliang Li,et al.  Role of Nrf2 in bone metabolism , 2015, Journal of Biomedical Science.

[27]  Jean X. Jiang,et al.  Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases , 2015, Journal of Bone and Mineral Metabolism.

[28]  S. Biswal,et al.  Nrf2 is required for normal postnatal bone acquisition in mice , 2014, Bone Research.

[29]  B. Dawson-Hughes,et al.  The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  A. Cuadrado,et al.  Effects of Nrf2 Deficiency on Bone Microarchitecture in an Experimental Model of Osteoporosis , 2014, Oxidative medicine and cellular longevity.

[31]  D. Galson,et al.  Pathobiology of Paget's Disease of Bone , 2014, Journal of bone metabolism.

[32]  W. Jeong,et al.  Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation. , 2013, Free radical biology & medicine.

[33]  M. Freeman,et al.  Loss of Nrf2 accelerates ionizing radiation-induced bone loss by upregulating RANKL. , 2012, Free radical biology & medicine.

[34]  B. Peng,et al.  Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. , 2012, The international journal of biochemistry & cell biology.

[35]  R. Recker,et al.  Benefits and risks of bisphosphonate therapy for osteoporosis. , 2012, The Journal of clinical endocrinology and metabolism.

[36]  T. Rachner,et al.  Osteoporosis: now and the future , 2011, The Lancet.

[37]  S. Manolagas.  From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. , 2010, Endocrine reviews.

[38]  H. Çelik,et al.  Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis , 2008, Rheumatology International.

[39]  S. Teitelbaum,et al.  The osteoclast: friend or foe? , 2008, Annual review of pathology.

[40]  D. Black,et al.  Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.

[41]  Soo Young Lee,et al.  A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. , 2005, Blood.

[42]  Colin R Dunstan,et al.  A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  S. Teitelbaum,et al.  Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.

[44]  K. Hruska,et al.  PTEN Regulates RANKL- and Osteopontin-stimulated Signal Transduction during Osteoclast Differentiation and Cell Motility* , 2003, The Journal of Biological Chemistry.

[45]  S. Ralston,et al.  Cytokine-activated endothelium recruits osteoclast precursors. , 2001, Endocrinology.

[46]  T. Martin,et al.  Therapeutic approaches to bone diseases. , 2000, Science.

[47]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[48]  H. Hanafusa,et al.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. , 1999, Molecular cell.

[49]  C. Rosen,et al.  The pathophysiology and treatment of postmenopausal osteoporosis. An evidence-based approach to estrogen replacement therapy. , 1997, Endocrinology and metabolism clinics of North America.

[50]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[51]  Michael T. Wilson,et al.  Bacterially induced bone destruction: mechanisms and misconceptions , 1996, Infection and immunity.

[52]  M. Seitz,et al.  Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus. , 1985, Annals of the rheumatic diseases.

[53]  R. Loeser,et al.  Targeting aging for disease modification in osteoarthritis , 2018, Current opinion in rheumatology.

[54]  K. Schröder.  NADPH oxidases in bone homeostasis and osteoporosis , 2014, Cellular and Molecular Life Sciences.

[55]  Matthew J. Silva,et al.  SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts , 2002, Nature Medicine.